Voyager shares take a hit as FDA slaps a hold on the IND for Huntington's gene therapy — their #2 play in the pipeline
A little more than a year after Sanofi handed back rights to Voyager’s $VYGR gene therapy program for Huntington’s in exchange for a cash payment, the biotech says the FDA has placed a hold on the IND needed to get into the clinic.
The word from Voyager — the FDA remains mute in these cases — is that the hold on VY-HTT01 deals with CMC issues, something that typically isn’t the kiss of death for a biotech company. But it will put the brakes on things for an uncertain period of time for Voyager, now helmed by Andre Turenne.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.